Journal
CLINICAL AND TRANSLATIONAL MEDICINE
Volume 4, Issue -, Pages -Publisher
JOHN WILEY & SONS LTD
DOI: 10.1186/s40169-015-0075-0
Keywords
KRAS mutant NSCLC; MAPK pathway; Targeted therapy
Categories
Funding
- UPCI LUNG SPORE [P50 CA9045440]
- LUNGevity Foundation
- V Foundation
- Sidney Kimmel Foundation for Cancer Research
- Doris Duke Charitable Foundation
Ask authors/readers for more resources
The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that target the RAS-RAF-MEK-ERK (MAPK) pathway have resulted in enhanced understanding of the KRAS mutant NSCLC and have provided optimism that this disease can be targeted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available